TOPICAL INDOMETHACIN FOR UVEITIS-RELATED MACULAR EDEMA

According to this study in Investigative Ophthalmology and Visual Science:

Purpose: Aim of the present randomized, double-blind, placebo-controlled clinical trial was to assess the efficacy and tolerability of 0.5% indomethacin eye drops in adult patients suffering from macular edema (ME) related to different aetiology uveitis. Methods:Forty-six eyes of thirty-one adult patients (20 females and 11 males) mean age 39 years, affected by inflammatory macular edema, were randomized to receive a dose of commercial 0.5% indomethacin eye-drops (INDOM®, Alfa Intes, Italy) four times a day (16 subjects = 23 eyes) or placebo (the vehicle of INDOM®, 15 subjects = 23 eyes) during a six months' active therapy follow-up. Study assessment at each visit included: visual acuity testing (VA), slit lamp examination, intra ocular pressure (IOP) evaluation and Heidelberg Spectralis Optical Coherence Tomography (OCT) central foveal thickness (CFT) measurement. Any variation in subjective symptoms and tolerability was also detected. Results:Statistical analysis showed, from baseline to 6 months' visit, a significant reduction in CFT (p<0 .0001="" 0.001="" 0.5="" a="" and="" blockquote="" both="" discomfort="" global="" group="" groups="" improvement="" in="" indomethacin-treated="" of="" only="" p="" present="" reduction="" significant="" symptoms="" the="" va="" was="">

Conclusions:The four-times-a-day administration of 0.5% indomethacin eye drops in eyes affected by uveitic ME from different etiologies, compared to placebo, is associated with a significant reduction in ME at six months follow-up visit, as measured by SD-OCT. However, not all eyes showed a complete resolution of ME because of vitreo-retinal traction.